Food allergy (FA) is a condition in which the body experiences an adverse immune response to specific dietary proteins. The introduction of biologic therapy has emerged as a promising treatment for this complex condition. This article discusses omalizumab, an anti-IgE monoclonal antibody that is the first in its class to be approved to address the underlying immunologic mechanisms driving FA.
Declining estrogen levels during menopause can contribute to the development of menopause-related vasomotor symptoms (VMS), such as hot flashes and night sweats. Moderate to severe VMS can significantly reduce quality of life and have substantial effects on physical and emotional well-being. Although hormone therapy is considered the most effective treatment for VMS, many women either refuse hormone therapy or have contraindications to it. This article discusses treatment approaches and considerations surrounding the 2 approved nonhormonal therapies for moderate to severe VMS.
